fipamezole
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2002 (NCT00040209)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Alpha-2b adrenergic receptorANTAGONIST
ADRA2B antagonist
- Adrenergic receptor alpha-2ANTAGONIST
Adrenergic receptor alpha-2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1- Mol. weight
- 230.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1255582 ↗
Also known as
- fipamezole
- fipamezole
- fipamezole
- fipamezole
- jp 1730
- jp 1730
- jp-1730
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00758849 | Phase 2 | Sep 1, 2008 | Juvantia Pharma Ltd, Santhera |
| NCT00559871 | Phase 2 | Oct 1, 2007 | Henry Ford Health System, Juvantia Pharma Ltd, Santhera |
| NCT00040209 | Phase 2 | Jun 1, 2002 | National Institute of Neurological Disorders and Stroke (NINDS) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Juvantia Pharma Ltd | For profit | 2 | 2 | 1 | 2007 |
| Santhera | For profit | 2 | 0 | 1 | 2007 |
| Henry Ford Health System | Academic/Hospital | 1 | 0 | 1 | 2007 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2002 |
4 organizations
Page 1 / 1